



## **Kala Pharmaceuticals to Present Data at ARVO 2013 Annual Meeting**

### *Preclinical Data Highlighting Kala's Proprietary Mucosal-Penetrating Particle Technology for Ocular Disease*

Waltham, Mass., May 3, 2013 – Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat a ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2013 Annual Meeting taking place May 5-9, 2013, in Seattle, WA. The poster presentation will highlight Kala's proprietary Mucosal-Penetrating Particle (MPP) technology as an optimal approach to enhanced topical delivery of receptor tyrosine kinase inhibitor (RTKi) for ocular disease.

#### **Poster Presentation:**

(Presentation #1087, Poster #C0064): Sunday, May 5, 2013, 1:00-2:45pmPT and 4:30-5:30pmPT, "Enhanced Topical Delivery of a Small Molecule Receptor Tyrosine Kinase Inhibitor (RTKi) via Mucosal-Penetrating Particle Technology," Lisa Schopf, Kala Pharmaceuticals, Poster Session #142, Drug Delivery I.

#### **About Kala Pharmaceuticals**

Kala Pharmaceuticals, Inc. is developing innovative products which are capable of penetrating mucosal barriers for the treatment of ocular diseases and diseases that affect the lungs, gastrointestinal tract, and female reproductive system. Mucosal barriers have been largely overlooked as a limitation for drug efficacy. Using the company's proprietary technology platform, Kala's Mucosal-Penetrating Products (MPPs) have the unique ability to rapidly and uniformly coat and permeate mucosal tissues leading to highly effective treatments with improved side effect profiles. The company is leveraging its platform as an internal product engine for a wide spectrum of potential applications, including treatments for respiratory, ophthalmic, female reproductive tract and gastrointestinal diseases. Kala is also pursuing collaborations with partners to transform the therapeutic properties of marketed drugs and compounds in development. Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, Dr. Justin Hanes of The Johns Hopkins University School of Medicine, Dr. Robert Langer of the Massachusetts Institute of Technology, and Dr. Colin Gardner formerly of TransForm Pharmaceuticals/Johnson & Johnson and Merck. The company is now backed by leading investors including Lux Capital, Polaris Venture Partners, Third Rock Ventures and, Crown Venture Fund, LLC. For more information, please visit [www.kalarx.com](http://www.kalarx.com).

#### **Contact:**

*Kala Pharmaceuticals, Inc.*

*Tel: 781 810 4748*

*info@kalarx.com*

**Media:**

*Gina Nugent*

*The Yates Network*

*gina@theyatesnetwork.com*